SCHEMBL1782842

SCHEMBL1782842

COC(=O)c1ccc(Oc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.69
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
MAPK14 Q16539 1/20 0.54
TRPV1 Q8NER1 1/20 0.53
MAPT P10636 3/20 0.51
KDM4E B2RXH2 1/20 0.51
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CYP1A1 P04798 1/20 0.49
CYP1B1 Q16678 1/20 0.49
PRSS1 P07477 1/20 0.49
ACR P10323 1/20 0.49
MAOB P27338 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385370 0.91 LMNA (0.60) LMNACA1CA2TRPV1MAPT
Ammonia Solution, Strong SCHEMBL27316369 0.89 LMNA (0.59) LMNACA1CA2TRPV1MAPT
SCHEMBL21656845 0.87 LMNA (0.58) LMNACA1CA2MAPTKDM4E
SCHEMBL21656479 0.87 LMNA (0.58) LMNACA1CA2MAPTKDM4E
SCHEMBL2271347 0.86 LMNA (0.56) LMNACA1CA2MAPTCES2
SCHEMBL13063663 0.86 LMNA (0.56) LMNACA1CA2MAPTCES2
SCHEMBL69218 0.85 CA1 (0.75) CA1CA2MAPTKDM4EMEN1
SCHEMBL694268 0.85 MAPT (0.61) LMNACA1CA2MAPK14MAPT
Methylene Chloride SCHEMBL28147089 0.84 LMNA (0.55) LMNACA1CA2MAPTCES2
SCHEMBL31575935 0.84 SRD5A2 (0.65) LMNACA1CA2TRPV1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600696-B2 Aromatic compounds Xeniopro GmbH (DE) 2026-04-14 US disclosed
US-20250346549-A2 NOVEL AROMATIC MOLECULES Xeniopro GmbH (DE) 2025-11-13 US disclosed
US-20250084023-A2 NOVEL AROMATIC MOLECULES Xeniopro GmbH (DE) 2025-03-13 US disclosed
US-20240140895-A1 NOVEL AROMATIC MOLECULES Xeniopro GmbH (DE) 2024-05-02 US disclosed
US-20230150923-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2023-05-18 US disclosed
US-11591289-B2 Aromatic compounds Xeniopro GmbH (DE) 2023-02-28 US disclosed
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2021-04-15 US disclosed
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2021-04-15 US disclosed
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2020-01-30 US disclosed
EP-2197551-B1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME (US) 2016-12-28 EP disclosed
US-8455638-B2 Soluble guanylate cyclase activators MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110118282-A1 Soluble Guanylate Cyclase Activators MERCK SHARP & DOHME LLC 2011-05-19 US disclosed
EP-2197551-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS Merck Sharp & Dohme Corp. (US) 2010-06-23 EP disclosed
US-20090209556-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME CORP. 2009-08-20 US disclosed
WO-2009032249-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK & CO., INC. (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150923-A1 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK LMNA 3327/4885CA1 4881/4885CA2 4416/4885
US-20250084023-A2 NOVEL AROMATIC MOLECULES AHR, TYR, MUSK LMNA 3829/4885CA1 4876/4885CA2 4410/4885
US-11591289-B2 Aromatic compounds AHR, TYR, MUSK LMNA 3083/4885CA1 4882/4885CA2 4221/4885
US-20110118282-A1 Soluble Guanylate Cyclase Activators GUCY1B1, GUCY1A2, GUCY1A1 LMNA 532/4885CA1 4658/4885CA2 3535/4885
US-20090209556-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1B1, GUCY1A2, GUCY1A1 LMNA 532/4885CA1 4658/4885CA2 3535/4885
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK LMNA 3327/4885CA1 4881/4885CA2 4416/4885
US-12600696-B2 Aromatic compounds CCR1, CCRL2, AHR LMNA 832/4885CA1 3602/4885CA2 1477/4885
US-20250346549-A2 NOVEL AROMATIC MOLECULES AHR, TYR, MUSK LMNA 3829/4885CA1 4876/4885CA2 4410/4885
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK LMNA 3327/4885CA1 4881/4885CA2 4416/4885
US-20240140895-A1 NOVEL AROMATIC MOLECULES AHR, TYR, MUSK LMNA 3829/4885CA1 4876/4885CA2 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.